Inflitza 25mg Capsule Supplier USA | Pharmaceutical Exporter from India

Inflitza 25mg Capsule: Advanced Midostaurin Therapy for AML and Mast Cell Disorders

Are you searching for a reliable Inflitza 25 mg capsule exporter from India? Ernest Oncology, a dedicated division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of specialized hematological treatments. We provide a high-authority, regulatory-compliant supply chain serving the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, ensuring that life-saving oncology medications reach healthcare providers with pharmaceutical-grade integrity and logistics excellence.

Detailed Product Overview: What is Inflitza 25mg?

Inflitza 25mg is an oral softgel capsule containing the active ingredient Midostaurin. Classified as a multitargeted kinase inhibitor, it is designed to disrupt the signaling pathways that allow certain types of cancer and blood disorders to thrive. Inflitza is a cornerstone in precision medicine, specifically targeting proteins that drive the overproduction of abnormal cells in the bone marrow and blood.

The 25mg strength is the standardized dosage unit, allowing for precise titration in complex treatment regimens, often used in combination with induction and consolidation chemotherapy.

Primary Therapeutic Indications:

Inflitza 25 mg is clinically indicated for the management of the following: 

1. Acute Myeloid Leukemia (AML): Specifically for newly diagnosed adult patients who are FLT3 mutation-positive. It is used in combination with standard cytarabine and daunorubicin chemotherapy.

2. Aggressive Systemic Mastocytosis (ASM): A rare disorder where too many mast cells build up in internal organs.

3. Systemic Mastocytosis with Associated Hematological Neoplasm (SM-AHN).

4. Mast Cell Leukemia (MCL): A highly aggressive form of mast cell disease.

Mechanism of Action: How Inflitza 25 mg Works: 

Inflitza 25mg functions by inhibiting several receptor tyrosine kinases involved in cell proliferation:

• FLT3 Inhibition: In patients with AML, it blocks the mutated fms-like tyrosine kinase 3 (FLT3) receptor. This stops the "growth signal" that tells leukemic cells to multiply uncontrollably.

• KIT Inhibition: It targets the proto-oncogene c-KIT (CD117). By blocking mutant KIT receptors, Inflitza reduces the proliferation of abnormal mast cells in systemic mastocytosis.

• Induction of Apoptosis: By disrupting these vital signaling pathways, the medication causes malignant cells to stop dividing and undergo programmed cell death (apoptosis).

Administration and Safety Guidelines: 

• Administration: Capsules should be taken orally twice daily (approximately 12 hours apart).

• Food Requirement: It is critical to take Inflitza with food to reduce the risk of gastrointestinal side effects like nausea and vomiting.

• Instruction: Swallow capsules whole. Do not open, crush, or chew the softgel.

• Safety Monitoring: Patients require regular monitoring of blood counts (CBC), heart function (ECG for QT prolongation), and lung health (monitoring for interstitial lung disease).

• Avoidances: Do not consume grapefruit or St. John's Wort during treatment, as these can interfere with the medication's effectiveness.

Why Source Inflitza 25 mg from Ernest Oncology?

• Global Exporter from India: Direct access to GMP-certified production, ensuring 100% authenticity and cost-effective bulk pricing.

• Seamless Logistics: Expertise in shipping to the USA, UK, UAE, Australia, and South Africa, including temperature-controlled handling where required.

• Bulk Supply Reliability: We maintain a consistent inventory of Inflitza (Midostaurin 25mg) to support large-scale hospital procurement and clinical tenders.

• Comprehensive Documentation: We provide all necessary Certificates of Analysis (COA) and export documentation for rapid customs clearance.